VivoSense, which is focused on advancing clinical research with wearable sensor solutions, provides specialist data analysis services, software and algorithm development.

The company will ingest data from several different wearable sensors including high-resolution cardiorespiratory and other cardiac sensors like Cardea SOLO to wrist-worn activity trackers.

The data from on-body sensors will be integrated, cleaned and will be analyzed synchronously, with algorithms and scientific oversight from its VivoSense platform. The solution will open all clinical trials for the accurate use of wearable technology, offering new level of data.

VivoSense co-founder and CEO Dudley Tabakin said: “Sophisticated new analytics are the key to making sense of the complex data sets generated by human study participants in response to new drug candidates and genetics-driven population health research. Using the class-leading Cardiac Insight Cardea SOLO ECG Sensor data with VivoSense software, data cleaning, robust analytics and regulatory-compliant biomarkers, we expect to enable new discoveries.

“The unique attributes and access to data enabled by Cardea SOLO strongly support our mission to advance clinical trials through the increasing use of wearable technology.”

The partnership between the two companies is expected to provide advanced insights into the performance of new medicines and therapies.

Cardiac Insight CEO Brad Harlow said the company’s partnership with VivoSense is forging new frontiers and capabilities in healthcare research.

Harlow said: “Our complex raw ECG data and automated analytics, easily obtained by our wearable ECG, Cardea SOLO, combined with the VivoSense platform integration will provide a new level of understanding into the effectiveness of emerging medical and pharmaceutical innovations, as well as to potentially develop completely new biomarkers.

“Contributing to the advancement of health research is an important component of our mission. We look forward to providing researchers a more comprehensive level of data analytics to improve disease prevention, detection and treatment.”

VivoSense stated that Comfortable and unobtrusive wearable cardiorespiratory sensors are now becoming very common, particularly in sports and fitness research, longitudinal healthcare monitoring, and in regulated clinical trials.

The large sets of physiological data generated by these sensors are considered to be key for monitoring health and providing a greater understanding of the effects of new medicines and therapies.